Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
JPY 309.0
(6.92%)
JPY 309.0
(6.92%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -107.33 Million | 631.92 Million | 339.17 Million | 163.43 Million | -155.06 Million | -114.49 Million |
| Net Income | 108.95 Million | 211.57 Million | 284.85 Million | -703 Million | -911.04 Million | -229.79 Million |
| Depreciation & Amortization | 345.45 Million | 445.75 Million | 470.08 Million | 484.31 Million | 465.23 Million | 468.26 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -259.26 Million | -221.24 Million | -68.57 Million | 455.02 Million | 639.12 Million | -353.4 Million |
| Other non-cash items | 245.33 Million | 195.83 Million | -347.19 Million | -72.89 Million | -348.38 Million | 441 Thousand |
| Investing Cash Flow | -2.35 Million | 17.13 Million | 50.57 Million | -199.51 Million | -178.71 Million | -205.47 Million |
| Investments in PPE | -555.68 Million | -211.16 Million | -368.14 Million | -482.25 Million | -207.26 Million | -596.32 Million |
| Acquisitions | - | -125.85 Million | -130.62 Million | -123.57 Million | -68.77 Million | 54.94 Million |
| Investment purchases | -41.78 Million | -22.87 Million | -3.06 Million | -2.92 Million | -2.84 Million | -2.79 Million |
| Sales/Maturities of investments | 578.07 Million | 251.17 Million | 421.78 Million | 285.66 Million | 31.39 Million | 113.38 Million |
| Other Investing Activities | 17.04 Million | 125.85 Million | 130.62 Million | 123.57 Million | 68.77 Million | 225.3 Million |
| Financing Cash Flow | -104.98 Million | -1.61 Million | -1.62 Million | -3.82 Million | -44.37 Million | -266.79 Million |
| Debt repayment | -1.05 Million | -1.05 Million | -1.05 Million | -3.23 Million | -40 Million | -160 Million |
| Dividends payments | -103.9 Million | -480 Thousand | -498 Thousand | -511 Thousand | -612 Thousand | -103.56 Million |
| Common Stock Repurchased | -36 Thousand | -75 Thousand | -62 Thousand | -84 Thousand | -66 Thousand | -109 Thousand |
| Common Stock Issuance | 11 Thousand | 1.05 Million | 1.05 Million | 3.23 Million | -3.69 Million | 71 Thousand |
| Other Financing Activities | -1000.00 | -1.06 Million | -1.06 Million | -3.23 Million | -1000.00 | -3.2 Million |
| Accounts receivables | 381.88 Million | -532.09 Million | -63.94 Million | 477.79 Million | 564.32 Million | -151.67 Million |
| Accounts payables | -185.63 Million | -112.69 Million | 299.66 Million | -522.81 Million | 17.79 Million | 261.77 Million |
| Inventory | -53.15 Million | 298.13 Million | -292.12 Million | 504.99 Million | 10.19 Million | -360.05 Million |
| Other working capital | -402.35 Million | 125.41 Million | -12.16 Million | -4.94 Million | 46.81 Million | -103.44 Million |
| Cash at beginning of period | 3.87 Billion | 3.23 Billion | 2.84 Billion | 2.88 Billion | 3.26 Billion | 3.84 Billion |
| Cash at end of period | 3.66 Billion | 3.87 Billion | 3.23 Billion | 2.84 Billion | 2.88 Billion | 3.26 Billion |
| Capital Expenditure | -555.68 Million | -211.16 Million | -368.14 Million | -482.25 Million | -207.26 Million | -596.32 Million |
| Effect of forex changes on cash | - | - | 1000.00 | - | -1000.00 | -2000.00 |
| Net cash flow / Change in cash | -214.67 Million | 647.43 Million | 388.12 Million | -39.9 Million | -378.14 Million | -586.76 Million |
| Free Cash Flow | -663.02 Million | 420.75 Million | -28.96 Million | -318.81 Million | -362.32 Million | -710.81 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 108.95 Million | 17.26 Million | -323.53 Million | 100.76 Million | 211.57 Million | 27.82 Million |
| Depreciation & Amortization | 345.45 Million | 103.86 Million | 99.65 Million | 99.74 Million | 445.75 Million | 107.01 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -259.26 Million | - | - | - | -221.24 Million | - |
| Other non-cash items | 245.33 Million | 86.6 Million | 423.18 Million | -1.02 Million | 195.83 Million | 79.19 Million |
| Investing Cash Flow | -2.35 Million | - | - | - | 17.13 Million | - |
| Investments in PPE | -555.68 Million | - | - | - | -211.16 Million | - |
| Acquisitions | - | - | - | - | -125.85 Million | - |
| Investment purchases | -41.78 Million | - | - | - | -22.87 Million | - |
| Sales/Maturities of investments | 578.07 Million | - | - | - | 251.17 Million | - |
| Other Investing Activities | 17.04 Million | - | - | - | 125.85 Million | - |
| Financing Cash Flow | -104.98 Million | - | - | - | -1.61 Million | - |
| Debt repayment | -1.05 Million | - | - | - | -1.05 Million | - |
| Dividends payments | -103.9 Million | - | - | - | -480 Thousand | - |
| Common Stock Repurchased | -36 Thousand | - | - | - | -75 Thousand | - |
| Common Stock Issuance | 11 Thousand | - | - | - | 1.05 Million | - |
| Other Financing Activities | -1000.00 | - | - | - | -1.06 Million | - |
| Accounts receivables | 381.88 Million | - | - | - | -532.09 Million | - |
| Accounts payables | -185.63 Million | - | - | - | -112.69 Million | - |
| Inventory | -53.15 Million | - | - | - | 298.13 Million | - |
| Other working capital | -402.35 Million | - | - | - | 125.41 Million | - |
| Cash at beginning of period | 3.87 Billion | 3.96 Billion | 4.18 Billion | 3.87 Billion | 3.23 Billion | 3.67 Billion |
| Cash at end of period | 3.66 Billion | 3.56 Billion | 3.96 Billion | 4.18 Billion | 3.87 Billion | 3.87 Billion |
| Capital Expenditure | -555.68 Million | - | - | - | -211.16 Million | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -214.67 Million | -401.18 Million | -222.8 Million | 305.23 Million | 647.43 Million | 200.16 Million |
| Free Cash Flow | -663.02 Million | 207.73 Million | 199.3 Million | 199.48 Million | 420.75 Million | 214.03 Million |
N3IA
6002
CRL
688305
VANTI
002720